Fetal Renal Artery Doppler Indices in Borderline Isolated Oligohydramnios

Status Recruiting

Clinical Trial Summary

The purpose of the study is to investigate third trimester fetal renal artery doppler indices in borderline idiopathic isolated oligohydramnios and relationship between neonatal outcomes.

Clinical Trial Description

During a routine pregnancy examination at 34-37 weeks gestation, the fetus was evaluated using ultrasound with the Toshiba Xario 200 3.5-megahertz probe. Fetal biometric measurements were obtained and placental structure and the amniotic fluid amount were evaluated in four quadrants. After detailed ultrasonography of the fetus, eligible pregnant women were included in the study.

Borderline idiopathic isolated oligohydramnios was defined according to the four quadrants technical with ultrasound examination and diagnosed with amniotic fluid index >5.0 and ≤8.0cm. After first ultrasound examination all patients in borderline isolated oligohydramnios group were hydrated with one to two liters of water daily. All patients monitored with non stress test and amniotic fluid index twice weekly until delivery after treatment with hydration.

For evaluating renal artery blood flow, an axial image of the fetal abdomen was obtained at the level of the fetal kidneys. Using color flow Doppler, the renal arteries were evaluated at the level of their origin from the abdominal aorta. The Doppler gate was placed within the lumen in a straight segment of the vessel. A minimum of three consecutive waveforms was used to calculate the PI. The umbilical artery Doppler measurements were studied in a free loop of cord, far from the fetus and placenta. pulsatile index and resistance index values were recorded.

The study consisted of two groups. The first group was formed of the patients who had normal amniotic volume and meets the inclusion criteria. In second group the investigators included patients who diagnosed borderline idiopathic isolated oligohydramnios. After delivery the investigators compared fetal renal artery doppler indices and neonatal outcomes between groups. ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Oligohydramnios

Clinical Trial Details

NCT number	NCT02901340
Study type	Observational
Source	Kayseri Education and Research Hospital
Contact	Erdem SAHIN, Study Principal Investigator
Phone	+095321688683
Email	erdemsahin07@hotmail.com
Status	Recruiting
Phase	N/A
Start date	August 2016
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03277417` - Does Amniotic Fluid Index Affect the Fetal Cardiac Performance?	N/A
Recruiting	`NCT00787163` - Amnioinfusion Initiative	Phase 3
Completed	`NCT05059093` - Developing and Testing AI Models for Fetal Biometry and Amniotic Volume Assessment in Fetal Ultrasound Scans.
Not yet recruiting	`NCT05043753` - "Fetal gRowth AbnorMality dEtection Trial"	N/A
Recruiting	`NCT02997345` - PPROM Registry (Preterm Premature Rupture of Membranes)
Completed	`NCT03935607` - The Added Contribution of Transvaginal Sonographic Evaluation of Amniotic Fluid Index
Completed	`NCT02581774` - Active Induction of Labor in Pregnancies Complicated With Oligohydramnios at Term	Phase 4
Terminated	`NCT01569035` - Warfarine in Unexplained Oligohydramnios	Phase 4
Completed	`NCT01140971` - Foley Catheter Versus Vaginal Misoprostol for Cervical Ripening and Induction of Labor	N/A
Recruiting	`NCT04684680` - The Role of Zamzam Water in Idiopathic Oligohydramnios	N/A
Not yet recruiting	`NCT03815968` - Low Sodium Diet in Oligohydramnios Assigned for Conservative Management	N/A
Enrolling by invitation	`NCT04451109` - Dilapan-S®: A Multicenter US E-registry
Terminated	`NCT01682928` - Hydrotherapy for the Reversal of Oligohydramnios	N/A
Not yet recruiting	`NCT05474326` - Effect of Intermittent Pneumatic Compression Device of Lower Limbs in Oligohydramnios	N/A
Completed	`NCT05332015` - The Effect of Oral Hypotonic Hydration in Isolated Oligohydramnios	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.